




September 30, 2026

6:30PM-8PM

Pharmacy & Therapeutics Committee Meeting

Formulary and Program Updates
Effective 1/1/2027



Roll Call

P&T COMMITTEE MEMBERS

David Konanc, MD

Jennifer Burch, PharmD, CDE

Ghassan Al-Sabbagh, MD

W. Russell Laundon, PharmD, MS, BCPS

Timothy Ashley, MD, MPH

Garland Moeller, MD

Stephen Hsieh, MD

Susan Moore, MD

PLAN STAFF & VENDORS

State Health Plan

- Tom Friedman, Executive Director
- Caroline Smart, Deputy Executive Administrator
- Jenny Vogel, PharmD, Sr. Clinical Pharmacist
- Toni Prine, RPh, Director of Pharmacy Operations, Pharmacy Benefits
- Justin Wylie, Web Designer

CVS Caremark

- Renée Jarnigan, RPh, Clinical Advisor

Ethics Awareness & Conflict of Interest Reminder

In accordance with the [Recusal Guidelines for Public Servants](#), it is the duty of every member of the Pharmacy & Therapeutics Committee, whether serving in a vote casting or advisory capacity, to avoid both conflicts of interest and appearances of conflict.

Does any Committee member have any known conflict of interest or the appearance of any conflict with respect to any manufacturers of any medication to be discussed at today's meeting?

Or, if during the course of the evaluation process if you identify a conflict of interest or the appearance of a conflict.

If so, please identify the conflict or appearance of conflict and refrain from any undue participation in the particular matter involved.

Minutes from Previous Committee Meeting

Instead of reading the minutes, copies were distributed prior to the meeting for your review.

- Are there any additions or corrections to the minutes?
- If not, the minutes will stand approved as is.

Proposed Formulary Updates – Effective 1/1/2027

Quarterly Formulary Updates:

- Formulary Additions (Line Extensions)
- Utilization Management
- Product Exclusions
- Tier Changes (Uptiers)

Presented by:

- Renée Jarnigan, RPh, Clinical Advisor, CVS Health
- Jenny Vogel, PharmD, Sr. Clinical Pharmacist, North Carolina State Health Plan

Formulary Updates – Line Extensions

Formulary Additions

- All Drugs, including **line extensions**, new formulations of existing formulary products and add backs (products not new to market that were previously blocked by the Plan and are now added to the formulary).

Therapeutic Category	Drug	Tier
Antineoplastic Agents/ Kinase Inhibitors	KOSELUGO (selumetinib) oral granules	6
Cardiovascular/ Pulmonary Arterial Hypertension	TYVASO DPI (treprostinil) 48-80MCG inhalation powder	6
Respiratory/ Anticholinergic/ Beta Agonist/ Steroid Combinations	BREZTRI AEROSPHERE 18 mcg (budesonide, glycopyrrolate, and formoterol fumarate) inhalation	2



 *North Carolina*
State Health Plan
FOR TEACHERS AND STATE EMPLOYEES
A Division of the Department of State Treasurer

Formulary Updates – Additions

Questions?

Auto-immune Indication Based Management Update

- Auto-immune therapy class is dynamic
 - High-cost launch pricing
 - Year-over-year inflation
 - Supplemental Indications
- Indication-Based Strategy manages utilization of specific drugs for specific indications rather than managing formulary placement at a therapy class level, allowing providers numerous preferred options
- Update for 1/1/2027 maintains SOTYKTU as a preferred product for plaque psoriasis but it will be blocked from coverage of psoriatic arthritis in favor of the Plan's other preferred formulary alternatives.
- An exception that may allow coverage of SOTYKTU for psoriatic arthritis requires a documented inadequate response, intolerable adverse reaction or contraindication to three of the formulary alternatives.

Drug Class	Target Product(s)	Formulary Options
Psoriatic Arthritis	SOTYKTU	tofacitinib, tofacitinib ext-rel, ADALIMUMAB-ADAZ, COSENTYX SC, ENBREL, HYRIMOZ, OTEZLA, RINVOQ, SKYRIZI SC, TREMFYA SC, YESINTEK SC

Utilization Management Efficiency

- CVS Caremark continues the utilization management (UM) optimization project initiated in 2024 to reduce overall prior authorization (PA) volume and friction with the PA process.
- Retiring UM criteria is an essential component of this process
- The primary focus for retirement of high-volume criteria is geared towards those that offer minimal value relative to member and prescriber burden as well as administrative costs.
- The following select criteria will be retired effective 10/1/2026:

Program Name
Cabenuva Specialty Guideline Management



Formulary Updates – Utilization Management Questions?

 *North Carolina*
State Health Plan
FOR TEACHERS AND STATE EMPLOYEES
A Division of the Department of State Treasurer

Formulary Updates – Product Exclusions

Standard Control Formulary – Exclusions

- Removals of certain high-cost drugs such as multisource brands that have lower cost generic alternatives available or other clinically effective lower cost options.

Formulary Exclusion Exception Process:

- This process is available to support Plan members who, per their provider, have a medical necessity to remain on an excluded drug.
- There may be circumstances in which the formulary alternatives may not be appropriate for some members. In this case, a member may be approved for the excluded drug with an exception process.
- An exception is defined as a situation where the member has tried and failed (that is, had an inadequate treatment response or intolerance) to the required number of formulary alternatives; or the member has a documented clinical reason such as an adverse drug reaction or drug contraindication that prevents them from trying the formulary alternatives.
- If a member's exception is approved that drug will be placed into Tier 3 or Tier 6 and the member will be subject to the applicable cost share.

Formulary Updates – Product Exclusions

Therapeutic Category	Drug	# Utilizers (6 mo.)	Formulary Preferred Alternatives
Immunologic Agents/ Autoimmune Agents (Self-Administered)	XELJANZ (tofacitinib) oral solution, oral tablet	28	tofacitinib
Immunologic Agents/ Autoimmune Agents (Self-Administered)	XELJANZ XR (tofacitinib ext-rel) oral extended-release tablet	113	tofacitinib ER
Respiratory/ Anticholinergics	umeclidinium inhalation powder, for oral inhalation	13	SPIRIVA

Formulary Updates – Product Exclusions (SHP)

Therapeutic Category	Drug	# Utilizers (6 mo.)	Formulary Preferred Alternatives
Antidiabetics (DPP4 Inhibitors)	JANUVIA (sitagliptin), ZITUVIO (sitagliptin)	1150	sitagliptin
Antidiabetic combination (DPP4 Inhibitors/Biguanide)	JANUMET (sitagliptin/metformin), ZITUVIMET (sitagliptin/metformin)	272	sitagliptin/metformin
Antidiabetic combination (DPP4 Inhibitors/Biguanide)	JANUMET XR (sitagliptin/metformin ER), ZITUVIMET XR (sitagliptin/metformin ER)	331	sitagliptin/metformin ER
Antineoplastic Enzyme Inhibitors	BOSULIF (bosutinib) tablets	7	bosutinib tablets
Pulmonary Fibrosis Agents	OFEV (nintedanib esylate)	12	nintedanib esylate

Formulary Updates – Product Exclusions (SHP)

Therapeutic Category	Drug	# Utilizers (6 months)	Formulary Preferred Alternatives
Viscosupplements	DUROLANE (hyaluronic acid) Intra-articular injection	109	methylprednisolone acetate, triamcinolone acetonide
Viscosupplements	EUFLEXXA (sodium hyaluronate) Intra-articular injection	40	methylprednisolone acetate, triamcinolone acetonide
Viscosupplements	GELSYN-3 (hyaluronic acid) Intra-articular injection	77	methylprednisolone acetate, triamcinolone acetonide
Viscosupplements	GENVISC 850 (hyaluronic acid) Intra-articular injection	0	methylprednisolone acetate, triamcinolone acetonide



Formulary Updates – Exclusions

Questions?

Formulary Updates – Uptier

Movement to Non-preferred Status

- Typically, branded medications that have readily available generic alternatives, biosimilars or other preferred formulary alternatives in the therapeutic class.
- All the following products will be moving from a lower tier to a higher tier.

Therapeutic Category	Drug	Current Utilizers	Tier Change
Central Nervous System, Antiseizure Agents	BRIVIACT (brivaracetam) intravenous solution, oral solution, oral tablet	71	2 → 3



Formulary Updates – Uptier

Questions?

Summary of Formulary Changes Effective 1/1/2027

FORMULARY ADDITIONS

- 3 products were added to the formulary

UTILIZATION MANAGEMENT

- Sotyktu Indication Based Management Update
- Retirement of Cabenuva SGM

PRODUCT EXCLUSIONS

- 15 products were excluded

UPTIERS

- 1 product had tier movements



 *North Carolina*
State Health Plan
FOR TEACHERS AND STATE EMPLOYEES
A Division of the Department of State Treasurer

New Business?

Upcoming Meeting Dates for 2027

- Wednesday, January 27, 2027
- Wednesday, April 28, 2027
- Wednesday, July 28, 2027
- Wednesday, September 29, 2027



Thank You.

